The authorisation follows the positive opinion recommending approval provided by the Committee for Medicinal Products for Human Use (CHMP). More: Waylivra granted conditional marketing authorisation in Europe Source: News
read moreThe disease that causes one-third of all AMR related deaths – drug-resistant tuberculosis (DR-TB) – is rarely talked about. More: AMR could cause 10 million deaths per year by 2050 Source: News
read moreThe approval is based on a clinical trial which showed that after an average of 30 months, the survival rate was higher in the Vyndaqel group. More: Pfizer's Vyndaqel, Vyndamax win US nod for rare disease Source: News
read moreIt’s the first substitution therapy approved in Europe to target the underlying cause of PKU by helping the body to break down Phe. More: EU approval for Palynziq in adult phenylketonuria Source: News
read moreThe drug was found to significantly increase the time patients live without disease progression. More: AZ’ Calquence trial to stop early after hitting endpoints Source: News
read moreArmed with new nods in asthma and adolescent eczema, Sanofi and Regeneron’s Dupixent continues its upward march. But an upcoming phase 3 study that aims to tap into COPD could be “much tougher,” Regeneron CEO Len Schleifer said. More: Dupixent's
read more© 1994 - 2026 B.M. Pharmaceuticals